MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Pacira BioSciences Total Assets 2011-2025 | PCRX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Pacira BioSciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.55 B | 1.57 B | 1.68 B | 2.08 B | 1.27 B | 831 M | 689 M | 628 M | 391 M | 390 M | 326 M | 170 M | 112 M | 113 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.08 B | 112 M | 844 M |
Quarterly Total Assets Pacira BioSciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.3 B | 1.54 B | 1.59 B | 1.55 B | 1.52 B | 1.65 B | 1.58 B | 1.57 B | 1.53 B | 1.54 B | 1.52 B | 1.68 B | 1.73 B | - | 1.89 B | 2.08 B | 1.36 B | 1.33 B | 1.29 B | 1.27 B | 1.27 B | 1.27 B | 1.27 B | 831 M | 831 M | 831 M | 831 M | 689 M | 689 M | 689 M | 689 M | 628 M | 628 M | 628 M | 628 M | 391 M | 391 M | 391 M | 391 M | 388 M | 388 M | 388 M | 388 M | 326 M | 326 M | 326 M | 326 M | 170 M | 170 M | 170 M | 170 M | 112 M | 112 M | 112 M | 112 M | 113 M | 113 M | 113 M | 113 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.08 B | 112 M | 827 M |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
286 M | $ 0.74 | -3.53 % | $ 52.6 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
918 M | $ 1.64 | -5.64 % | $ 176 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
18.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
1.93 B | $ 3.03 | -7.49 % | $ 1.61 B | Canada |
 |
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
853 M | $ 5.12 | -5.19 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
1.82 B | $ 12.12 | 6.13 % | $ 621 M | USA |
 |
Evoke Pharma
EVOK
|
7.07 M | $ 10.96 | 0.09 % | $ 36.6 M | USA |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | $ 21.4 | 0.16 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
233 M | $ 7.16 | 1.7 % | $ 444 M | USA |
 |
Harrow Health
HROW
|
312 M | $ 46.04 | -2.17 % | $ 1.5 B | USA |
 |
China Pharma Holdings
CPHI
|
14.9 M | $ 1.55 | -0.26 % | $ 27.1 M |  China |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 6.86 | -0.87 % | $ 2.5 B | Canada |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
498 M | $ 4.78 | -0.93 % | $ 629 M | USA |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.78 | -7.55 % | $ 402 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
75.6 M | $ 3.02 | 19.37 % | $ 42.5 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
223 M | - | - | $ 193 M | Canada |
 |
Rockwell Medical
RMTI
|
52.2 M | $ 0.88 | -5.2 % | $ 20.5 M | USA |
 |
Solid Biosciences
SLDB
|
189 M | $ 5.8 | -1.28 % | $ 237 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
13.7 M | $ 3.51 | -2.11 % | $ 4.36 M | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
97.6 M | $ 4.34 | 6.9 % | $ 131 M | USA |
 |
Jupiter Wellness
JUPW
|
7.34 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
9.65 B | $ 12.83 | -2.36 % | $ 1.76 B | USA |
 |
ProPhase Labs
PRPH
|
87.6 M | $ 0.11 | -2.7 % | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
Veru
VERU
|
60.4 M | $ 2.44 | 0.83 % | $ 329 M | USA |
 |
Sundial Growers
SNDL
|
1.35 B | $ 1.94 | -12.22 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
10.6 M | $ 1.25 | 4.17 % | $ 5.39 M | USA |
 |
SCYNEXIS
SCYX
|
128 M | $ 0.64 | -0.56 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
4.31 B | $ 11.11 | -8.56 % | $ 6.87 B | Canada |
 |
TherapeuticsMD
TXMD
|
43.3 M | $ 1.73 | -1.14 % | $ 18.1 M | USA |
 |
Zomedica Corp.
ZOM
|
253 M | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
50 B | $ 11.69 | 0.34 % | $ 14.2 B | USA |